Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes

Priya Vart; Muthiah Vaduganathan; Niels Jongs; Giuseppe Remuzzi; David C. Wheeler; Finnian R. Mc Causland; Glenn M. Chertow; Hiddo J.L. Heerspink

doi:10.2215/cjn.08900722

Back

Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes

Article 2022 en

Abstract

1 min read

Benazepril for Advanced Chronic Renal Insufficiency, NCT00270426, and a Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (Dapa-CKD), NCT03036150.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2014

Abstract 12684: Cardiorenal Outcomes and the Efficacy of Darbepoetin in Patients With Heart Failure, Reduced Ejection Fraction, Anemia and Advanced Chronic Kidney Disease

Akshay S. Desai, Henry Krum, Changhong Yu, Scott M. Wasserman, Eduard Apetrei, Vijay Chopra, Mareev VIu, Aldo Maggioni, John J.V. McMurray, Marc A. Pfeffer, Karl Swedberg, James B. Young

Article2010

THE DIABETIC CKD PATIENT—A MAJOR CARDIOVASCULAR CHALLENGE

I.M. van der Meer, Piero Ruggenenti, Giuseppe Remuzzi

Editorial Material2024

Mineralocorticoid receptor antagonist for chronic kidney disease, risk or benefit?

Bi Huang, Garry McDowell, Anirudh Rao, Professor Gregory Lip

Article2023

DAPA-HF applicability: the point of view of a cardiology setting

Massimo Iacoviello, Marco Marini, Mauro Gori, Francesco Orso, Lucio Gonzini, Marco Gorini, Peter Fenici, Aldo Maggioni

Article2025

#1394 Endothelin-1 and cardio-kidney events among patients with CKD, diabetes, and anemia

Finnian R. Mc Causland, B Claggett, Petr Jarolı́m, Martina M. McGrath, Emmanuel A. Burdmann, Andrew S. Levey, John J.V. McMurray, Giuseppe Remuzzi, Scott D Solomon, Marc A. Pfeffer